Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 12582408.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A total of 26 postmarketing cases of allergic contact dermatitis to doxepin 5% cream were reported to the Food and Drug Administration. Our findings suggest that allergic contact dermatitis was more common when treatment duration exceeded the recommended 8 days. Allergic contact dermatitis to doxepin cream should be considered in patients whose condition fails to improve or worsens with doxepin use.
Medical subject headings
- Antipruritics
- Dermatitis, Allergic Contact
- Doxepin
- Product Surveillance, Postmarketing